Psoriasis Therapeutics - Pipeline Assessment and Market Forecasts to 2018

Sept. 28, 2011 - PRLog -- GlobalData estimates that the global psoriasis therapeutics market was worth $3.6 billion in 2010 and forecasts it to grow at a compound annual growth rate (CAGR) of 8.1% to reach $6.7 billion by 2018. This high growth forecast is primarily attributed to the currently approved drugs reaching their peak sales and the launch of first-in-class molecules during the forecast period.

For patients with moderate to severe psoriasis, the current treatment options offer reasonable clinical outcomes. Nevertheless, standard treatments are associated with long-term toxicity, side effects, and inconvenience. Therefore, the global psoriasis therapeutics market is attractive, with a high unmet need for a cure of the underlying cause of the disease. This unmet need in the market is high for topical and conventional systemic therapy and moderate for biologics. The unmet need arises due to the moderate efficacy and safety profile of the marketed drugs.

The psoriasis therapeutics market is underserved by the currently marketed drugs as no drug can provide a fundamental cure for the disease. There is a relatively brief remission after discontinuation of therapy and the current options are associated with serious adverse events. Therefore, the market provides an opportunity for new entrants if they have a convenient route of administration/schedule, an enhanced long term efficacy and safety profile and cost effectiveness.


For Sample Pages, please click or add the below link to your browser:
http://www.globaldata.com/reportstore/RequestSamplePages....


GlobalData found the psoriasis therapeutics pipeline to be strong. It consists of 95 molecules in different stages of development. There are approximately 50 first-in-class molecules with better safety and efficacy profiles. There are six molecules in the Phase III stage of clinical development. Molecules such as Tofacitinib, Apremilast and Briakinumab are expected to enter the psoriasis therapeutics market in the forecast period. A strong clinical pipeline, coupled with high unmet need, is expected to drive the future psoriasis therapeutics market.

GlobalData, the industry analysis specialist, has released its new report, “Psoriasis Therapeutics - Pipeline Assessment and Market Forecasts to 2018”. The report is an essential source of information and analysis on the global Psoriasis Therapeutics market. The report identifies the key trends shaping and driving the global Psoriasis Therapeutics market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global Psoriasis Therapeutics sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.



For further details, please click or add the below link to your browser:
http://www.globaldata.com/reportstore/Report.aspx?ID=Psor...

Visit our report store: http://www.globaldata.com/reportstore

For more details contact:
pressreleases@globaldata.com
           
North America:    +1 646 395 5477
Europe:        +44 207 753 4299
           +44 1204 543 533
Asia Pacific:       +91 40 6616 6782

# # #

GlobalData is a global market intelligence services company providing information research and analysis products and services.